Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Melatonin stimulates the nonamyloidogenic processing of βaPP through the positive transcriptional regulation of ADAM10 and ADAM17
Authors: Mayuri Shukla
Htut Htut Htoo
Phitchayapak Wintachai
Jean Francois Hernandez
Claire Dubois
Rolf Postina
Huaxi Xu
Frédéric Checler
Duncan R. Smith
Piyarat Govitrapong
Bruno Vincent
Mahidol University
Institut des Biomolecules Max Mousseron
Universite de Sherbrooke
Johannes Gutenberg Universitat Mainz
Xiamen University
Sanford Burnham Prebys Medical Discovery Institute
Universite Nice Sophia Antipolis
CNRS Centre National de la Recherche Scientifique
Keywords: Biochemistry, Genetics and Molecular Biology
Issue Date: 1-Jan-2015
Citation: Journal of Pineal Research. Vol.58, No.2 (2015), 151-165
Abstract: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Melatonin controls many physiological functions including regulation of the circadian rhythm and clearance of free radicals and neuroprotection. Importantly, melatonin levels strongly decrease as we age and patients with Alzheimer's disease (AD) display lower melatonin than age-matched controls. Several studies have reported that melatonin can reduce aggregation and toxicity of amyloid-β peptides that are produced from the β-amyloid precursor protein (βAPP). However, whether melatonin can directly regulate the βAPP-cleaving proteases ('secretases') has not been investigated so far. In this study, we establish that melatonin stimulates the α-secretase cleavage of βAPP in cultured neuronal and non-neuronal cells. This effect is fully reversed by ADAM10- and ADAM17-specific inhibitors and requires both plasma membrane-located melatonin receptor activation, and ERK1/2 phosphorylation. Moreover, we demonstrate that melatonin upregulates both ADAM10 and ADAM17 catalytic activities and endogenous protein levels. Importantly, genetic depletion of one or the other protease in mouse embryonic fibroblasts prevents melatonin stimulating constitutive and PKC-regulated sAPPα secretion and ADAM10/ADAM17 catalytic activities. Furthermore, we show that melatonin induces ADAM10 and ADAM17 promoter transactivation, and we identify the targeted promoter regions. Finally, we correlate melatonin-dependent sAPPα production with a protection against staurosporine-induced apoptosis. Altogether, our results provide the first demonstration that melatonin upregulates the nonamyloidogenic ADAM10 and ADAM17 proteases through melatonin receptor activation, ERK phosphorylation and the transactivation of some specific regions of their promoters and further underline the preventive rather than curative nature of melatonin regarding AD treatment.
ISSN: 1600079X
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.